Value through Innovation12 February 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

28.09.2015

COPD: New data support role of Spiolto® Respimat® as 1st-line maintenance therapy and show superiority over LABA/ICS

27.09.2015

VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone

27.09.2015

ECC 2015: GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status

25.09.2015

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

25.09.2015

New data show only 40% of physicians treating advanced lung cancer considered extension of life to be the most important treatment goal after first-line chemotherapy

22.09.2015

Boehringer Ingelheim Animal Health launches two new swine vaccines in Europe

21.09.2015

ERS 2015: Landmark year for Boehringer Ingelheim’s respiratory portfolio - new data for COPD, IPF and asthma treatments

21.09.2015

Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD

17.09.2015

Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

16.09.2015

Asthma: U.S. FDA approves new indication for SPIRIVA® Respimat®

-  
15.09.2015

Type 2 diabetes: International survey shows quality of patient-physician conversation at diagnosis linked to better patient outcomes

15.09.2015

EASD: Additional Evidence Showed ABASAGLAR® (insulin glargine) Provided Safety and Efficacy Similar to Lantus®

08.09.2015

New data show that more than 50% of patients and carers struggled to cope with challenges of living with lung cancer

07.09.2015

European Medicines Agency (EMA) approves the use of Ingelvac CircoFLEX® during pregnancy and lactation in sows

01.09.2015

Boehringer Ingelheim licenses Vectron Biosolutions’ expression technology platform

29.08.2015

ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim

28.08.2015

Expansion of the Boehringer Ingelheim Board of Managing Directors / Andreas Neumann responsible for Human Resources

25.08.2015

FDA and EMA accept regulatory applications for Boehringer Ingelheim’s Giotrif® / Gilotrif® (afatinib) for treatment of advanced squamous cell carcinoma of the lung